Med. Pro Praxi 2007; 4: 172-176 [Urolog. pro Praxi, 2006; 3: 102-107]

Farmakologická léčba hyperaktivního močového měchýře

MUDr. Michael Pešl, MUDr. Libor Zámečník, prof. MUDr. Tomáš Hanuš DrSc, MUDr. Viktor Soukup, MUDr. Ivan Pavlík, prof. MUDr. Jan Dvořáček DrSc
Urologická klinika 1. LF UK a VFN Praha

Hyperaktivní močový měchýř (overactive bladder – OAB) je syndrom charakterizovaný kombinací symptomů – urgence, časté nucení k mikci a urgentní inkontinence. Pro stanovení diagnózy OAB nemusí být přítomny všechny vyjmenované symptomy najednou a nemusí být provedeno urodynamické vyšetření. Prevalence OAB je v naší populaci relativně vysoká a postupně se zvyšuje tak, jak populace stárne. Tím se stává nejen zdravotním, ale i socioekonomickým problémem. V poslední době je tomuto problému věnována velká pozornost jak mezi lékaři pečujícími o pacienty s OAB, tak mezi farmaceutickými firmami, které se snaží vyvinout ideální lék na léčbu OAB. Toto sdělení má za cíl podat přehled o současných možnostech farmakologické léčby OAB.

Keywords: hyperaktivní močový měchýř, muskarinové receptory

Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pešl M, Zámečník L, Hanuš T, Soukup V, Pavlík I, Dvořáček J. Farmakologická léčba hyperaktivního močového měchýře. Med. praxi. 2007;4(4):172-176.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003; 62(5 Suppl. 2): 28-37. Go to original source... Go to PubMed...
    2. Abrams P, Amarenco G, Bakke A, Buczynski A, astro-Diaz D, Harrison S, Kamer G, Marsik R, Prajsner A, Stohrer M a kol. European tamsulosin neurogenic urinary tract dysfunction study group. Tamsulosin: efficacy and safety in patiens with neurogenic urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003; 170: 1242-1251. Go to original source... Go to PubMed...
    3. Abrams P, Freeman R, Anderstrom C a kol. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutinin in patiens with an overactive bladder. Br J Urol 1998; 81: 801-810. Go to original source... Go to PubMed...
    4. Anderson K. Pharmacological treatment of urinary incontinence. Abrams P, Cardovo L, Khoury S, Sein A, editors. 2nd Consultation on Incontinence, Paris 2001. Plymouth: Plymbridge Distributors Ltd.: 2002. p. 479-511.
    5. Andersson KE. Advances in the pharmacological control of the bladder. Exp Physiol 1999; 84: 195-213. Go to original source... Go to PubMed...
    6. Andersson KE. Changes in bladder tone during filling: Pharmacological aspects. Scand J Urol Nephrol 1999; 201: 67-72. Go to original source... Go to PubMed...
    7. Andersson KE. Pathways for relaxation of detrusor smooth muscle. In Baskin L, Hayward S (eds): Advances in Bladder Research. New York, Plenum, 1999; 241-252. Go to original source...
    8. Bolduc S, Upadhay J, Patron Ja kol. The use of tolterodine in childrenafter oxybutinin failure. BJU International 2003; 91: 398-401. Go to original source... Go to PubMed...
    9. Castelden CM, George CF, Renwick AG, et al. Imipramine-a possible alternative to current therapy for urinary incontinence in the elderly. J Urol 1981; 125: 218-221. Go to original source... Go to PubMed...
    10. Cole A, Fried F. Favorable experiences with imipramine in the treatment of neurogenic bladder. J Urol 1972; 107: 44-48. Go to original source... Go to PubMed...
    11. England RC, Norman RI, Elliott RA. Direct inhibition of rat detrusor muscle contraction by erytromycin. Neurol Urodyn 2004; 23(3): 273-279. Go to original source... Go to PubMed...
    12. Edwards G, Henshaw M, Miller M, Weston AH. Comparison of the effects of several pottasium-channel openers on the rat bladder and the rat portal vein in vitro. Br J Pharmacol 1991; 102(3): 679-680. Go to original source... Go to PubMed...
    13. Gruneberger A. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride. Br J Obstet Gynecol 1984; 91: 275-280. Go to original source...
    14. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Cost of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004; 63(3): 461-465. Go to original source... Go to PubMed...
    15. Chapple CR, Martinez-Garcia R, Selvaggi L a kol. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464-470. Go to original source... Go to PubMed...
    16. Jonáš U, Hofner K, Madesbacher H a kol. Efficacy and safty of two doses of tolterodine varsus placebo in patiens with detrusor overactivity and symptoms of frequency, urge incontinence and urgency: urodynamic evaluation. World J Urol 1997; 15: 144-151. Go to original source... Go to PubMed...
    17. Lose G, Jorgensen L, Thunebord P. Doxepin in the treatment of female detrusor overactivity: A randomized double-blind crossover study. J Urol 1989; 142: 1024-1028. Go to original source... Go to PubMed...
    18. Milsom I, Abrams P, Cardovo L, Roberts RG, Thuroff J, Sein AJ. How widespread are the symptoms of an overactive bladder and how are they manager? A population-based study. BJU Int 2001; 87(9): 760-766. Go to original source... Go to PubMed...
    19. Nilvebrant L, Sundquist S, Gillberg PG. Interaction of tolterodine with cholinegric muscarinic receptors in human detrusor. Neurourol Urodyn 196; 15: 310-311.
    20. Nilvebrant L, Hallen B, Larson G a kol. Tolterodine - a new bladder selective muscarinic receptor antagonist: preclinical pharmacolgical and clinical data. Life Sci 1997; 60: 1129-1136. Go to original source... Go to PubMed...
    21. Nilvebrant L, Anderson K, Gillberg PG a kol. Tolterodine - a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Eur J Pharmacol 1997; 327: 195-207. Go to original source... Go to PubMed...
    22. Norlen L, Sundin T, Waagstein F. Beta-adrenoceptor stimulation of the human urinary bladder in vivo. Acta Pharmacol Toxicol 1978; 43: 5-10. Go to original source... Go to PubMed...
    23. Norton Pl, Karrom M, Wall LL, et al. Randomized double blind trial of terodilene in the treatment of urge incontinence in women. Obstet Gynecol 1994; 84: 386-390. Go to PubMed...
    24. Ohraje A, Ukai M, Hatanaka T a kol. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over solivary gland in rats. Eur J Pharmacol 2004; 492: 243-250. Go to original source... Go to PubMed...
    25. Reuter K, Aagoard J. Sloha adrenergic blockade in the diagnosis of detrusor instability secondary to intravesical obstruction. Urol Int 1984; 39: 312-313. Go to original source... Go to PubMed...
    26. Sant GR. Intravesical 50 % dimethyl sulfoxide (RIMSO-50) in treatment of interstitial cystitis. Urology 1987; 29(Suppl 4): 17-21. Go to original source... Go to PubMed...
    27. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20(6): 327-336. Go to original source... Go to PubMed...
    28. Yamanouchi. Data on file. 2005.
    29. Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology 2002; 59 (5 Suppl 1): 25-29. Go to original source... Go to PubMed...
    30. Zderic SA, Levin RM, Wein AJ. Voiding function: Relevant anatomy, physiology, pharmacology and molecular aspects. In Gillenwater JY, Howards SS, Grayhack JT, Duckett JW: Adult and Pediatric Urology, 3rd ed. Chicago, Mosby-Year Book, 1995, 1159-1219.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.